Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ras-related protein Rab-5A (RAB5A)
- Target
- RAB5A
- Molecular classification
- Small GTPase, Enzyme, Ras superfamily member, Regulatory protein
01
Overview
Ras-related protein Rab-5A (RAB5A) is a small GTPase of the Rab family, part of the Ras superfamily, which acts as a molecular switch to regulate endocytic vesicle trafficking, especially the early stages of endosome fusion[1][2][5]. It cycles between inactive (GDP-bound) and active (GTP-bound) states, controlling the recruitment of effector proteins and facilitating membrane fusion involved in nutrient uptake, receptor downregulation, and antigen presentation[2][7]. RAB5A participates in several signaling pathways, including autophagy and the mTOR signaling pathway, and interacts with various regulators and effectors responsible for endosomal dynamics[2][5]. Dysregulation of RAB5A has been implicated in tumorigenesis, neurodegeneration (notably Alzheimer’s disease), and metabolic disturbances, making it a subject of interest for biomarker development and targeted therapy strategies[2][7].
- Other names
- Ras-related protein Rab-5ARAB5RAS-associated protein RAB5ARab5
02
Mechanism of action
Small molecule inhibition of GTPase activity; Modulation of endocytic trafficking and organelle fusion
03
Biological functions
Regulation of endocytic pathwayEarly endosome fusion and traffickingNutrient uptakeDownregulation of receptors and signaling cascadesAntigen presentationAutophagy pathway regulationmTOR signaling modulation
04
Disease associations
CancerNeurodegenerative disease (including Alzheimer’s disease)Metabolic disease (e.g., diabetes)Other (potential involvement in infection and immune regulation)
05
Safety considerations
Targeting RAB5A could disrupt essential cellular trafficking and homeostasisPotential effects on neuronal cell function and metabolism if inhibited systemically
06
Interacting drugs
No widely established FDA-approved drugs directly target RAB5A, but inhibitors and modulators are under experimental investigation, particularly for cancer applications[2].
07
Biomarkers
Aberrant RAB5A expression levels (especially upregulation) may serve as a biomarker in cancer and neurodegenerative disease contexts[2].
Beyond the preview
Go deeper on Ras-related protein Rab-5A (RAB5A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ras-related protein Rab-5A (RAB5A).